Skip to main content
Terug
ADPT logo

Adaptive Biotechnologies Corporation

Datakwaliteit: 100%
ADPT
NASDAQ Healthcare Biotechnology
€ 13,66
▲ € 0,08 (0,59%)
Marktkapitalisatie: 2,10B
Dagbereik
€ 13,55 € 14,12
52-Weeksbereik
€ 6,68 € 20,76
Volume
1.228.656
50D / 200D Gem.
€ 16,24 / € 14,47
Vorige Slotkoers
€ 13,58

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -35,4 0,4
P/B 9,6 2,9
ROE % -28,2 3,8
Net Margin % -21,5 3,9
Rev Growth 5Y % 15,7 10,0
D/E 1,3 0,2

Koersdoel Analisten

Hold
€ 21,25 +55.6%
Low: € 21,00 High: € 22,00
Forward WPA
-€ 0,48
Omzet Sch.
280 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 -€ 0,01
-€ 0,01 – -€ 0,01
640 M 2
FY2029 € 0,09
€ 0,08 – € 0,09
510 M 2
FY2028 -€ 0,06
-€ 0,29 – € 0,06
420 M 4

Belangrijkste Punten

Revenue grew 15,74% annually over 5 years — strong growth
Negative free cash flow of -48,95M
PEG of 0,65 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 39,03%
Capital efficient — spends only 1,07% of revenue on capex

Groei

Revenue Growth (5Y)
15,74%
Revenue (1Y)54,77%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-28,23%
ROIC-8,58%
Net Margin-21,48%
Op. Margin-20,62%

Veiligheid

Debt / Equity
1,28
Current Ratio3,34
Interest Coverage-4,85

Waardering

P/E Ratio
-35,35
P/B Ratio9,61
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 54,77% Revenue Growth (3Y) 27,54%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 15,74% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 276,98M Net Income (TTM) -59,50M
ROE -28,23% ROA -11,60%
Gross Margin 74,24% Operating Margin -20,62%
Net Margin -21,48% Free Cash Flow (TTM) -48,95M
ROIC -8,58% FCF Growth (3Y) N/A
Safety
Debt / Equity 1,28 Current Ratio 3,34
Interest Coverage -4,85 Dividend Yield 0,00%
Valuation
P/E Ratio -35,35 P/B Ratio 9,61
P/S Ratio 7,59 PEG Ratio 0,65
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 2,10B Enterprise Value 2,31B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 276,98M 178,96M 170,28M 185,31M 154,34M
Net Income -59,50M -159,49M -225,25M -200,19M -207,28M
EPS (Diluted) -0,39 -1,08 -1,56 -1,00 -1,46
Gross Profit 205,62M 106,88M 94,72M 127,40M 105,04M
Operating Income -57,12M -162,55M -227,04M -200,19M -208,97M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 512,74M 539,38M 661,13M 856,62M 923,34M
Total Liabilities 287,74M 336,89M 352,86M 392,52M 319,24M
Shareholders' Equity 218,79M 202,71M 308,40M 464,17M 603,99M
Total Debt 280,58M 89,39M 98,77M 108,00M 111,74M
Cash & Equivalents 70,50M 47,92M 65,06M 90,03M 139,07M
Current Assets 300,19M 283,75M 410,19M 562,15M 402,75M
Current Liabilities 89,92M 98,05M 88,02M 109,79M 113,81M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#63 of 146
48

Recente Activiteit

Ingestapt Full Throttle
Mar 24, 2026